Oncolytics Biotech (ONCY) Prnewswire·2025-02-19 12:00Core Insights - Oncolytics Biotech Inc. is making significant progress in 2025 with its immunotherapy pelareorep, particularly in pancreatic cancer and other hard-to-treat cancers [1][2][4] - The company has received regulatory clearance to advance its pancreatic cancer study and presented new efficacy and safety data at the 2025 ASCO Gastrointestinal Cancers Symposium [1][2][4] Regulatory Developments - The German Regulatory Agency has approved the continuation of the pancreatic cancer study, allowing full enrollment after a positive safety review [3][6] - The study involves 30 patients in Stage 1, evaluating pelareorep in combination with modified FOLFIRINOX and atezolizumab [6][9] Clinical Data and Efficacy - New clinical results presented at ASCO GI 2025 demonstrate pelareorep's potential in pancreatic and anal cancers, indicating strong safety and efficacy signals [4][6] - Patients receiving pelareorep with atezolizumab show stronger responses than expected based on previous studies with checkpoint inhibitors alone [6] Future Milestones - Oncolytics is entering a pivotal year with multiple upcoming milestones, including additional data readouts and interactions with regulatory agencies [5][7] - The company is preparing for registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA [12]